Phase 2 study initiated to evaluate jaguar health's crofelemer for microvillus inclusion disease (mvid), an ultrarare congenital diarrheal disorder

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (iit) and two phase 2 studies - of crofelemer for the rare disease indications of mvid and/or short bowel syndrome with intestinal failure (sbs-if) in the us, eu, and/or middle east/north africa regions; availability of first iit proof-of-concept results potentially in q1 2025 crofelemer, jaguar's novel plant-based prescription drug, has been granted orphan-drug designation by the fda and the european medicines agency (ema) for both mvid and sbs-if san francisco, ca / accesswire / december 18, 2024 / jaguar health, inc. (nasdaq:jagx) (jaguar) family companies napo pharmaceuticals (napo) and napo therapeutics today announced that napo's phase 2 study to evaluate the efficacy of crofelemer, jaguar's novel plant-based anti-secretory prescription drug, for the indication of mvid in pediatric patients, has been initiated. "the initiation of this double blind, placebo-controlled study in pediatric mvid patients is a key milestone for jaguar," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking